The future of human health will be defined by technologies that accelerate the world's access to more effective medicines.
Human cells are a cornerstone of fundamental disease research, drug discovery, and clinical translation. Yet, despite decades of research into iPSCs, emerging cures for some of the world’s most pervasive diseases have been bottlenecked by a lack of access to standardised, easy to use and readily accessible human cells.
We built ioCells to solve this challenge.
Developed on our platform, and powered by opti-ox technology, ioCells are human cells precision reprogrammed from iPSCs consistently, at scale. With ioCells, scientists no longer need to battle with variance, unreliability, physiological irrelevance and long experimental timelines. Instead, scientists can finally focus on the next great advances in human health.
ioCells are for research use only.
ioWild Type Cells™
ioWild Type Cells are defined, easy-to-use, functional iPSC-derived human cells from a healthy donor background that are ready for fundamental research and drug discovery experimentation within days.
ioDisease Model Cells™
ioDisease Model Cells are ioWild Type Cells engineered to contain disease-relevant mutations. ioDisease Model Cells and ioWild Type Cells form an isogenic pair allowing scientists to make true comparisons.
ioCRISPR-Ready Cells™
ioCRISPR-Ready Cells are human iPSC-derived cells constitutively expressing Cas9 nuclease for rapid gene knockout generation.
Custom Cell Development
We provide our partners with the ability to develop and access any human cell type at scale, removing the experimental burden of cell models that are not translatable, scalable or an accurate representation of disease
Consistent
Our platform ensures consistency between every batch of cells, overcoming the challenge of data reproducibility.
Cost-effective
ioCells generate quality data at industry leading seeding densities. You can do more with every vial as every well saves you money.
Defined
Every ioCell has its identity characterised by ICC, RT-qPCR and RNA-Seq at minimum.
Easy-to-use
ioCells are delivered cryopreserved and require a simple protocol using an open-source medium to get started.
Quick
Precision reprogrammed cells mature rapidly, meaning cells are ready for experimentation and data gathering within days post-revival.
Scalable
With opti-ox technology we can make billions of consistently reprogrammed cells, surpassing the demands of industrial workflows.
Every ioCell is powered by opti-ox.
Using opti-ox, populations of stem cells are precisely and consistently reprogrammed into a chosen cell identity. Each vial of ioCells contains a defined and highly characterised population of iPSC-derived human cells that are ready for quality data production in a matter of days. Their high lot-to-lot consistency provides a reliable cell model that enables scientists to conduct repeatable and scalable experiments in drug discovery and disease research.
Emmanouil Metzakopian | Vice President, Research and Development | bit.bio
Javier Conde-Vancells | Director Product Management | bit.bio
Whitehouse, et al
JoVE Journal of Visualized Experiments
2023
Using ioGlutamatergic Neurons
Dr Ania Wilczynska | Head of Computational Genomics | Non-Clinical | bit.bio
Innovation showcase talk at ISSCR
Marius Wernig MD, PhD | Stanford
Mark Kotter, MD, PhD | bit.bio
Oosterveen, et al
bit.bio & Charles River Laboratories
2023
Mark Kotter | CEO and founder | bit.bio
Marius Wernig | Professor Departments of Pathology and Chemical and Systems Biology | Stanford University
Madeleine Garrett | Field Application Specialist | bit.bio
Ritsma et al
Charles River Laboratories & bit.bio
2022
Ritsma, et al
Charles River Laboratories & bit.bio
2022
Raman, et al
bit.bio
2022
Pavinlek, et al
Frontiers in Psychiatry
2022
Using ioGlutamatergic Neurons
Bando, et al
Frontiers in Cellular and Infection Microbiology
2022
Using ioGlutamatergic Neurons
Mah, et al
Experimental Neurology
2022
Using ioGlutamatergic Neurons
Dr Deepak Srivastava | King’s College London
Dr Marijn Vlaming | Head of Biology, et al.
Charles River & bit.bio
Dr Marijn Vlaming | Head of Biology
Charles River
Kam Dhaliwal | SVP Strategic Alliances | bit.bio
Talk at ELRIG CRISPR in Drug Discovery
Lachize, et al
Courtesy of Charles River Laboratories
2020
Kam Dhaliwal | SVP Strategic Alliances | bit.bio
Dr Thomas Moreau | Head of Research | bit.bio
Talk at ELRIG Drug Discovery Digital